



CONTINUOUS MONONUCLEAR CELL (CMNC) COLLECTION

ADVANCING THERAPEUTIC APHERESIS AND CELL
COLLECTIONS TO THE NEXT LEVEL OF PATIENT CARE

TERUMOBCT

Unlocking the Potential of Blood

SPECTRA OPTIA® APHERESIS SYSTEM

Giving you versatility and customization


The Spectra Optia system allows you to perform efficient mononuclear cell (MNC) collections. With this procedure, you can collect MNCs including monocytes, lymphocytes, CD34+ and dendritic cells. Additionally, you can customize each procedure to meet the specific needs of each donor or patient.

Procedure and System Highlights

Consistent results	Automated Interface Management (AIM) system is designed to produce consistent results through interface stability
Streamlined processing	CMNC collection through single-stage processing
Procedural flexibility	<p>Versatile software is designed for a wide range of device interaction preferences and operator skill levels</p> <p>Operator controls:</p> <ul style="list-style-type: none">Inlet flow rate (5 mL/min to 142 mL/min)Collect pump flow rate (0.5 mL/min to 10 mL/min)Packing factor (1 to 20)Collection preference (10 to 90) <p>Gives you the ability to specify how much plasma to collect into the plasma bag or collection bag.</p>
Minimal system interactions	Allows you to spend more focused time with your patients
Intuitive graphical user interface	Streamlines your procedure management with touch-screen instructions and simple data entry

LABORATORY STUDY

A controlled laboratory study was conducted to compare the Spectra Optia system CMNC collection protocol to the COBE Spectra system MNC protocol using twelve split pools of type-matched human whole blood. Key outcome measures included: MNC, CD34+ and platelet collection efficiencies, run time, measures of product purity and the concentration of platelets in collected plasma. Comparison of the two protocols across this broad range of outcome measure confirmed the equivalency of the two procedures. Contact your Terumo BCT representative for additional performance data.



How it Works

THE PERFORMANCE YOU EXPECT

The AIM system provides continuous interface monitoring, interpretation and adjustment for efficient MNC collection.

- Monitors the collect port and interface position up to 25 times per second with a resolution of approximately 10 microns
- Interprets interface information using a patented optical detection system
- Adjusts the pumps and valves to manage the interface position and efficiently remove the targeted components

CONTINUOUS PROCESSING

WHOLE BLOOD ENTERS THE CHANNEL

The packing factor and channel design allow for the separation of white blood cells (WBCs).


INTERFACE ESTABLISHED


- AIM system quickly establishes the interface at the collect port
- Buffy Coat accumulates
- AIM system controls the concentration of cells by adjusting the plasma pump flow rate

RED BLOOD CELLS (RBCs) AND PLASMA PUMPED BACK TO THE PATIENT

TARGETED CELLS CONTINUOUSLY PUMPED INTO THE COLLECTION BAG

You may monitor and adjust the depth at which the cells are collected within the Buffy Coat layer based on the desired hematocrit of the collected product; you may also adjust the collect pump flow rate to further optimize your collection.





Low volume tubing set Extracorporeal Volume (ECV) = 253 mL (typical), 297 mL (maximum)*	Supports patient comfort and safety Lower ECV under normal operating conditions than the COBE Spectra system WBC set (285 mL)*
Functionally closed	Reduces the risk of microbial contamination of the collected product
Compact packaging	Minimizes the space required for storage
Color-coded components	Simplifies setup and operation

*Under normal operating conditions, the ECV will not exceed the typical ECV value. Under certain infrequent alarm conditions, such as during reservoir recovery after a reservoir alarm, the ECV may momentarily increase to the maximum ECV value.

Working with You

Each and every interaction we have with you is important. By fostering open and ongoing relationships, we bring more value to you and the patients we are all focused on serving.

Even after the technology is in place, we continue to provide you with:

- Education and training
- Technical support
- Clinical and scientific support
- Customer support
- Users groups and professional networks

TERUMOBCT

Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies. We believe in the potential of blood. This belief inspires our innovation and strengthens our collaboration with customers.

UNLOCKING THE POTENTIAL OF BLOOD | TERUMOBCT.COM

Terumo BCT, Inc. 10811 West Collins Ave. Lakewood, Colorado 80215-4440 USA USA Phone: 1.877.339.4228 Phone: +1.303.231.4357 Fax: +1.303.542.5215	Terumo BCT Europe N.V. Europe, Middle East and Africa Ikaroslaan 41 1930 Zaventem Belgium Phone: +32.2.715.05.90 Fax: +32.2.721.07.70	Terumo BCT (Asia Pacific) Ltd. Room 3903-3903A, 39/F ACE Tower, Windsor House 311 Gloucester Road Causeway Bay, Hong Kong Phone: +852.2283.0700 Fax: +852.2576.1311	Terumo BCT Latin America S.A. La Pampa 1517-12th Floor C1428DZE Buenos Aires Argentina Phone: +54.11.5530.5200 Fax: +54.11.5530.5201	Terumo BCT Japan, Inc. 20-14, 3-chome Higashi Gotanda, Shinagawa-ku Tokyo, 141-0022 Japan Phone: +81.3.6743.7890 Fax: +81.3.6743.9800
---	--	--	---	--